Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

48.25 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Dec 2, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

83 84 Next >

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

January 30, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts? ↗

January 30, 2024

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Via Benzinga

Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)

January 30, 2024

From Bristol Myers Squibb

Via Business Wire

Is Bristol Myers Squibb Stock a Buy Now? ↗

January 25, 2024

This healthcare stock has seen healthier days.

Via The Motley Fool

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

January 30, 2024

EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END

Via FinancialNewsMedia

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

January 29, 2024

Via Get News

Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients ↗

January 29, 2024

Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo.

Via Benzinga

Uncovering Dividend Opportunities with NYSE:BMY. ↗

January 25, 2024

Analyzing BRISTOL-MYERS SQUIBB CO (NYSE:BMY)'s Dividend Potential.

Via Chartmill

Behind the Scenes of Bristol-Myers Squibb's Latest Options Trends ↗

January 16, 2024

Via Benzinga

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

January 29, 2024

--News Direct--

Via News Direct

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

January 29, 2024

New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug...

Via TheNewswire.com

Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial

January 27, 2024

From Bristol Myers Squibb

Via Business Wire

Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? ↗

January 29, 2024

An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.

Via Benzinga

Topics Artificial Intelligence

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)

January 26, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

3 Healthcare Stocks at 52-Week Lows: Buy or Bye? ↗

January 26, 2024

Investors should consider picking up these healthcare stocks at 52-week lows to benefit from their potential rebound.

Via InvestorPlace

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

January 26, 2024

From Bristol Myers Squibb

Via Business Wire

Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer' ↗

January 24, 2024

FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list.

Via Benzinga

7 Beaten-Down Value Stocks Poised for an Epic Turnaround ↗

January 23, 2024

Battered value stocks could be priced for an epic rebound in 2024 and beyond. These seven can quickly escape Wall Street's penalty box.

Via InvestorPlace

Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study ↗

January 23, 2024

Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.

Via Benzinga

Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio

January 23, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup ↗

January 23, 2024

Bristol Myer's Opdivo/Yervoy's long-term survival benefits in CheckMate-214 trial for advanced renal cell carcinoma. Significant reductions in risk of death, improved OS, PFS, and ORR after eight...

Via Benzinga

Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment ↗

January 23, 2024

In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.

Via Benzinga

Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

January 22, 2024

From Bristol Myers Squibb

Via Business Wire

January 22, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

January 22, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers' Lead Cancer Immunotherapy Shows Progression Free Survival Versus Chemo In Certain Type Of Colorectal Cancer ↗

January 22, 2024

Bristol Myers' Opdivo + Yervoy combo shows 79% reduced risk in MSI-H/dMMR metastatic colorectal cancer.

Via Benzinga

Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial

January 20, 2024

From Bristol Myers Squibb

Via Business Wire

Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes ↗

January 19, 2024

Ikena Oncology optimizes resources for targeted oncology programs IK-930 & IK-595. Clinical updates expected H2 2024. Workforce reduced by 35%. Financially secure with $175M cash. Strategic focus on...

Via Benzinga

Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering? ↗

January 18, 2024

Pharmaceuticals prices are already up in 2024: Can inflation-beating hikes be justified?

Via Benzinga

Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers

January 17, 2024

From Bristol Myers Squibb

Via Business Wire

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

83 84 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.